• About us
• Contact

Advertisement

Organisation › Details

Indivumed GmbH

Indivumed has established the world’s leading high-content tumor database and highest-quality biobank to support the development of new cancer companion diagnostics and therapies. Aside from having implemented a highly standardized biospecimen collection process and a unique clinical infrastructure with clinical partners in Germany and the US, Indivumed offers a broad range of specialized research services to biopharmaceutical companies and academia and actively performs a cancer biomarker development program. With its subsidiary IndivuTest GmbH, Indivumed provides high-quality tissue-based tumor analysis to patients and started an initiative with oncologists in Germany and the US to improve personalized cancer therapy strategies in the clinical routine. *

 

	Start	2002-04-01 established
	Group	Indivumed (Group)
	Predecessor	Israelitisches Krankenhaus Hamburg
	Industry	clinical research
	Person	Juhl, Hartmut (Indivumed 200701 CEO + founder)
	Person 2	Bastian, Helge (Thermo Fisher 201406 General Manager Synthetic Biology before Indivumed + Sigma-Aldrich + SGS + Qiagen)
	Region	Hamburg
	Country	Germany
	Street	88 Falkenried Haus D
	City	20251 Hamburg
	Tel	+49-40-413383-10
		Address record changed: 2022-09-18
Basic data	Employees	D: 101 to 500 (2022-01-17)
		* Document for »About Section«:
		Record changed: 2024-12-29

Advertisement

More documents for Indivumed (Group)

• [1] Crown Bioscience, Inc.. (4/4/23). "Press Release: Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank". San Diego, CA....
• [2] Indivumed GmbH. (1/25/23). "Press Release: Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank". San Diego, CA & Hamburg....
• [3] Indivumed GmbH. (9/7/22). "Press Release: Indivumed and CellPhenomics Announce Partnership for Improved Cancer Patient Care". Berlin & Hamburg....
• [4] Indivumed GmbH. (1/17/22). "Press Release: Accelerated Drug Development and Personalised Treatments for Cancer. Indivumed Receives EU Funding from ERDF Structural Fund". Hamburg....
• [5] Indivumed GmbH. (12/12/21). "Press Release: Indivumed Appoints Dr. Stephan Schüller as CFO"....
• [6] Indivumed GmbH. (8/10/21). "Press Release: Veraxa Biotech and Indivumed Cooperate on the Development of Precision Oncology Antibody Drugs". Heidelberg & Hamburg....
• [7] Indivumed GmbH. (6/2/21). "Press Release: Indivumed Launches the nRavel AI Platform for Cancer Research and Drug Development". Hamburg....
• [8] Indivumed GmbH. (5/17/21). "Press Release: Indivumed Joins KHR Biotec, Expands Partnership with University Medical Center Mainz". Hamburg....
• [9] Indivumed GmbH. (3/18/21). "Press Release: Indivumed Announces Expansion into Drug Development, Formation of Ix Therapeutics. Joint Venture with Xlife Sciences". Hamburg....
• [10] Indivumed GmbH. (1/26/21). "Press Release: Indivumed Appoints Roald Forsberg as New Chief Business Officer". Hamburg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.